Following the highly successful FCG/YCP Webinar Series held earlier this year, SCI’s Fine Chemicals Group and Young Chemists' Panel (FCG and YCP) are proud to host further webinars to support learning and development for chemists in industry and academia. These online sessions provide a global platform for chemists worldwide and we hope that you will join us in the upcoming series of webinars demonstrating high quality chemistry in an accessible format.
The next webinar will feature two, paired, 25 minute presentations from chemists sharing their knowledge and expertise in sustainable process chemistry.
Registration for this lecture is currently free, made possible by our generous sponsors. If you or your organisation would be interested in supporting this webinar, or those in the future, please contact email@example.com
Tuesday 6 October
Talk 1: Homogeneous ester hydrogenation has the potential for displacing the use of hydrides in fine chemical production, providing more cost-effective processes for the synthesis of primary alcohols with much reduced environmental impact, Dr Antonio Zanotti Gerosa, Johnson Matthey
Talk 2: Structured reactors under inductive heating, Professor Evgeny Rebrov, School of Engineering, University of Warwick
Tuesday 20 October
Talk 1: Is resistance futile? – discovery of a broad spectrum mutant c-KIT inhibitor as a novel cancer therapeutic, Dr James M.Smith, AstraZeneca
Talk 2: Venture in new target space: Drugging the DUBs, Professor Tim Harrison, Queen's University Belfast
School of Engineering, University of Warwick
Evgeny Rebrov is Chair of the Energy Intensified Chemical Reactor Engineering Lab in the School of Engineering at the University of Warwick and part-time professor at the Department of Chemical Engineering & Chemistry, Eindhoven University of Technology. He got his PhD in Chemistry (Cum lauda) from Boreskov Institute of Catalysis (Novosibirsk, Russia) in 1999 and his DSc in Chemical Engineering from Lomonosov Moscow University of Fine Chemical Technology in 2012. He is also co-founder and director of Stoli Catalysts Ltd, a spin-out company of the University of Warwick. His research focuses on the development of advanced chemical reactors for catalytic (gas-liquid) processes. Prof. Rebrov has published > 180 scientific papers in peer-reviewed journals and 9 book chapters and provided > 55 invited talk at scientific conferences and seminars. He is a recipient of several highest EU awards: ERC Starting grant (2011), ERC Proof of Concept (2015) and ERC Synergy (2018) and SME Stage2 Instrument grant (2019).
Johnson Matthey LST
• Studied Chemistry in Milano (Laurea in 1991 and Dottorato in 1994 with Prof Maiorana);
• Studentships and postdoctoral positions in London (Prof Ley, 1991) , Bonn (Prof Doetz, 1994), Lausanne (Prof Floriani, 1995-97) and Nagoya (Prof. Noyori, 1998);
• Joined Chirotech in Cambridge, UK in 1997, where he started working on industrial applications of homogeneous catalysis, especially chiral reductions;
• Since 2003 he has been working at Johnson Matthey, Cambridge, UK, as a Team Leader and later as R&D Director, leading a team involved in the development of homogeneous catalysts and their applications.
Queen's University, Belfast
Following a PhD in organic chemistry at Nottingham University with Gerry Pattenden and Postdoctoral studies at the University of California with Larry Overman, Tim joined Merck’s Neuroscience Research Centre in Harlow, UK, where he rose to the position of Director, Medicinal Chemistry. Whilst at Merck he was part of the team which discovered the marketed Substance P antagonist Emend®. In 2007, Tim moved to Northern Ireland to set up Almac Discovery, a biotech company based in Belfast focused on modulation of the ubiquitin system, and the development of next generation protein-drug conjugates, where he is currently VP Drug Discovery. Tim also holds an academic position at the Patrick G Johnston Centre for Cancer Research at Queen’s University, Belfast, where he is the McClay Professor of Medicinal Chemistry, and his research focuses on apoptosis and drug resistance. He currently splits his time between his Almac role and his academic position, and is author or inventor on over 140 papers and patents.
Originally from Bristol, I completed both my undergraduate MChem and PhD degrees at The University of Manchester (PhD under supervision of Prof. John D. Sutherland). Following this I completed post-doctoral studies first at the Institute of Cancer Research in London, and then at the University of Edinburgh (with Prof. Michael Greaney). I next settled to continue research as a Medicinal Chemist in the field of cancer therapeutics at Cancer Research UK Discovery Laboratories in Cambridge in 2008. I moved to join AstraZeneca in Cambridge in 2014, where I now lead a team of medicinal chemists and have contributed to multiple cancer drug discovery projects across the AZ portfolio.
Sign up as an Event Member to join this event.
Tel: +44 (0)20 7598 1561